HDL and Diabetes

Blake J Cochran; Bikash Manandhar; Kerry-Anne Rye

doi:10.1007/978-981-19-1592-5_9

HDL and Diabetes

Adv Exp Med Biol. 2022:1377:119-127. doi: 10.1007/978-981-19-1592-5_9.

Authors

Blake J Cochran¹, Bikash Manandhar¹, Kerry-Anne Rye²

Affiliations

¹ Lipid Research Group, Faculty of Medicine, School of Medical Sciences, University of New South Wales Sydney, Sydney, NSW, Australia.
² Lipid Research Group, Faculty of Medicine, School of Medical Sciences, University of New South Wales Sydney, Sydney, NSW, Australia. k.rye@unsw.edu.au.

PMID: 35575925
DOI: 10.1007/978-981-19-1592-5_9

Abstract

Diabetes is a worldwide public health issue, with the number of cases expected to reach 642 million by 2040. Patients with diabetes are at a two- to four-fold increased risk of developing cardiovascular disease. This chapter focuses on the anti-diabetic and cardioprotective functions of plasma high-density lipoproteins (HDLs). HDLs and the main HDL apolipoprotein, apoA-I, improves pancreatic beta cell function. ApoA-I also improves insulin sensitivity. The development of novel, bifunctional HDL-based interventions are a promising therapeutic option for the treatment of cardiometabolic diseases.

Keywords: Antidiabetic; Diabetes; Insulin sensitivity; β cell.

MeSH terms

Apolipoprotein A-I
Cardiovascular Diseases*
Diabetes Mellitus, Type 2*
Humans
Insulin-Secreting Cells*
Lipoproteins, HDL

Substances

Apolipoprotein A-I
Lipoproteins, HDL